Fmr LLC Has $656.98 Million Stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

FMR LLC grew its position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 11.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,159,208 shares of the company's stock after buying an additional 866,328 shares during the quarter. FMR LLC owned approximately 15.64% of PROCEPT BioRobotics worth $656,979,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Signaturefd LLC grew its holdings in PROCEPT BioRobotics by 26.7% during the 4th quarter. Signaturefd LLC now owns 689 shares of the company's stock worth $55,000 after acquiring an additional 145 shares during the last quarter. Naviter Wealth LLC raised its position in PROCEPT BioRobotics by 6.0% in the 4th quarter. Naviter Wealth LLC now owns 3,089 shares of the company's stock worth $249,000 after purchasing an additional 176 shares during the last quarter. Amundi lifted its holdings in PROCEPT BioRobotics by 0.9% during the 4th quarter. Amundi now owns 20,143 shares of the company's stock worth $1,742,000 after buying an additional 183 shares in the last quarter. Arizona State Retirement System boosted its position in PROCEPT BioRobotics by 1.5% in the 4th quarter. Arizona State Retirement System now owns 14,285 shares of the company's stock valued at $1,150,000 after buying an additional 218 shares during the last quarter. Finally, KRS Capital Management LLC increased its stake in shares of PROCEPT BioRobotics by 0.5% in the 4th quarter. KRS Capital Management LLC now owns 46,455 shares of the company's stock valued at $3,741,000 after buying an additional 225 shares during the period. Institutional investors and hedge funds own 89.46% of the company's stock.

Analyst Ratings Changes

PRCT has been the topic of several recent research reports. Morgan Stanley decreased their price target on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Truist Financial dropped their price target on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a research note on Friday. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $91.43.

PROCEPT BioRobotics Trading Up 2.2 %

Shares of PRCT traded up $1.12 during trading hours on Monday, reaching $53.19. The stock had a trading volume of 111,936 shares, compared to its average volume of 775,136. The firm has a 50-day moving average of $60.84 and a 200 day moving average of $75.50. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. The company has a market cap of $2.92 billion, a P/E ratio of -27.28 and a beta of 1.09. PROCEPT BioRobotics Co. has a 52 week low of $47.04 and a 52 week high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The business had revenue of $68.24 million for the quarter, compared to analyst estimates of $66.79 million. On average, sell-side analysts expect that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

Insider Buying and Selling at PROCEPT BioRobotics

In related news, CFO Kevin Waters sold 733 shares of the firm's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the sale, the chief financial officer now directly owns 107,991 shares in the company, valued at $6,161,966.46. This trade represents a 0.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Reza Zadno sold 5,475 shares of the company's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $312,403.50. Following the completion of the transaction, the chief executive officer now directly owns 173,070 shares of the company's stock, valued at approximately $9,875,374.20. The trade was a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 6,455 shares of company stock valued at $368,322. 17.40% of the stock is currently owned by corporate insiders.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).